Systematic review on the safety of the use of quinolones in the pediatric population
DOI:
https://doi.org/10.56294/sctconf2024941Keywords:
Fluoroquinolones, Pediatric Safety, Cartilage Toxicity, Adverse EffectsAbstract
Background: the safety of fluoroquinolones in the pediatric population has been a matter of concern due to the potential for adverse effects such as growth cartilage toxicity. Despite their broad antimicrobial spectrum and efficacy, the prescription of fluoroquinolones in children and adolescents is limited by the risk of arthralgias and other side effects. This study aims to evaluate the safety of fluoroquinolones in pediatric patients and the impact of regulatory actions on their prescription.
Method: a systematic review of studies investigating the safety of fluoroquinolones in the pediatric population was conducted. Studies that met specific inclusion criteria were selected, and relevant information on the decrease in fluoroquinolone prescriptions and their adverse effects was extracted.
Results: in the study on the safety and tolerability of quinolones in the pediatric population, 22 % (199/904) of patients experienced adverse events following treatment with quinolones. Gastrointestinal disorders, such as nausea and diarrhea, were the most frequent, affecting 12 % (108/904) of patients. This was followed by skin rashes and effects on the central nervous system, at 5 % (45/904) and 3 % (27/904) respectively. Moxifloxacin demonstrated good tolerability across all age cohorts, without significant joint or neuropathic adverse findings. Specific safety studies of moxifloxacin confirmed its safety, showing no significant differences in safety variables compared to other antibiotics.
Conclusion: it is crucial to continue monitoring the safety of fluoroquinolones in the pediatric population to ensure an adequate balance between the benefits and risks of their use
References
1. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J. 2003;22(12):1128-32. doi: 10.1097/01.inf.0000101994.25947.12. PMID: 14688586.
2. Khalili S, Imtirat A, Williams S, Ali A, Tehrani N, Mireskandari K. Safety of intracameral moxifloxacin in the pediatric population: an equivalence study. J Cataract Refract Surg. 2020 Feb;46(2):228-234. doi: 10.1097/j.jcrs.0000000000000018. Erratum in: J Cataract Refract Surg. 2020 Aug 1;46(8):1212. PMID: 32126036.
3. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532. doi: 10.1164/rccm.2021020509OC. PMID: 33734030; PMCID: PMC8483230.
4. Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S55-63. doi: 10.1016/j.survophthal.2005.05.004. PMID: 16257311.
5. Mandell L, Tillotson G. Safety of fluoroquinolones: An update. Can J Infect Dis. 2002 Jan;13(1):54-61. doi: 10.1155/2002/864789. PMID: 18159374; PMCID: PMC2094848.
6. Stass H, Lettieri J, Vanevski KM, Willmann S, James LP, Sullivan JE, Arrieta AC, Bradley JS. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. J Clin Pharmacol. 2019 May;59(5):654-667. doi: 10.1002/jcph.1358. Epub 2019 Jan 25. PMID: 30681729; PMCID: PMC9252262.
7. Jordi Vila, Adelaide A Hebert, Antonio Torrelo, Yuly López, Marta Tato, María García-Castillo & Rafael Cantón (2019) Ozenoxacin: a review of preclinical and clinical efficacy, Expert Review of Anti-infective Therapy, 17:3, 159-168, DOI: 10.1080/14787210.2019.1573671
8. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672. PMID: 22383668; PMCID: PMC3435140.
9. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672. PMID: 22383668; PMCID: PMC3435140.
10. Poetker DM, Lindstrom DR, Patel NJ, Conley SF, Flanary VA, Link TR, Kerschner JE. Ofloxacin otic drops vs neomycin-polymyxin B otic drops as prophylaxis against early postoperative tympanostomy tube otorrhea. Arch Otolaryngol Head Neck Surg. 2006 Dec;132(12):1294-8. doi: 10.1001/archotol.132.12.1294. PMID: 17178938.
11. Roberts, Matthew & Scott, Susan & Harris, Patrick & Naber, Kurt & Wagenlehner, Florian & Doi, Suhail. (2018). Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World Journal of Urology. 36. 10.1007/s00345-017-2163-9.
12. Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 2009 Mar;29(2):189-95. doi: 10.1097/BPO.0b013e3181982c4f. PMID: 19352246; PMCID: PMC2988490.
13. Shin JY, Kim MH, Shin SM, Lee SH, Park BJ. Dramatic decrease in fluoroquinolones in the pediatric population in Korea. Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1320-4. doi: 10.1002/pds.3696. Epub 2014 Aug 14. PMID: 25124740.
Published
Issue
Section
License
Copyright (c) 2024 Vinícius Cardoso da Mata, Estrin Marcelo Adrian (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
